ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01672 ASCLETIS-B

Closed 08-18 16:08:05

10.000

-0.450

-4.31%

High10.560	Low9.985	Vol1.80M
Open10.370	D1 Closing10.450	Amplitude5.50%
Mkt Cap10.52B	Tradable Cap10.52B	Total Shares1.05B
T/O18.67M	T/O Rate0.17%	Tradable Shares1.05B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"ASCLETIS-B","latestPrice":10,"timestamp":1787040485004,"preClose":10.45,"halted":0,"volume":1803000,"delay":0,"changeRate":-0.04306220095693773,"floatShares":1052000000,"shares":1052000000,"eps":-0.3701,"marketStatus":"Closed","change":-0.45,"latestTime":"08-18 16:08:05","open":10.37,"high":10.56,"low":9.985,"amount":18668410,"amplitude":0.055024,"askPrice":10.01,"askSize":8000,"bidPrice":10,"bidSize":52000,"shortable":3,"etf":0,"ttmEps":-0.379,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787103000000},"marketStatusCode":5,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":10.45,"openAndCloseTimeList":[[1787016600000,1787025600000],[1787029200000,1787040000000]],"volumeRatio":1.416737,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672/wiki","defaultTab":"wiki","newsList":[{"id":"2658128927","title":"Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2658128927","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658128927?lang=en_us&edition=fundamental","pubTime":"2026-08-12 15:30","pubTimestamp":1786519859,"startTime":"0","endTime":"0","summary":"Ascletis Pharma (SEHK:1672) has drawn fresh attention after launching two Phase I obesity trials in the U.S. and starting a global Phase III program for its oral GLP-1 candidate ASC30.\nSee our latest analysis for Ascletis Pharma.\nThe recent obesity pipeline updates arrive after a mixed share price run for Ascletis Pharma. The stock rose 13.29% over a 7 day share price return but remains down 37.61% over a 90 day share price return and has recorded a 26.41% decline on the 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-at-5x-p-b-on-obesity-trial-momentum","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-at-5x-p-b-on-obesity-trial-momentum","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658193554","title":"Ascletis Pharma Begins Obesity Drug Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193554","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193554?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:55","pubTimestamp":1786362947,"startTime":"0","endTime":"0","summary":"Ascletis Pharma (HKG:1672) initiated two phase I studies in the U.S. for ASC36 and ASC36_35FDC for the treatment of obesity.The move comes following investigational new drug clearance by the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","01672","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118689402","title":"Ascletis Launches U.S. Phase I Trials for Potential First-in-Class Monthly Obesity Injections ASC36 and ASC36_35FDC","url":"https://stock-news.laohu8.com/highlight/detail?id=1118689402","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118689402?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:06","pubTimestamp":1786360006,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. (Ascletis) has begun two Phase I clinical studies in the United States to evaluate novel, ultra-long-acting peptide therapies for obesity, following recent Investigational New...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980079","title":"Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: Asc36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and Asc36_35Fdc Once-Monthly Injection, a Co-Formulation of Asc36 and Glp-1R/Gipr Peptide Agonist Asc35","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980079?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470PG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159859212","title":"Ascletis-B Launches Two Phase 1 Obesity Studies in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=1159859212","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159859212?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:57","pubTimestamp":1786359439,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has announced that, following Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), it has initiated two Phase 1 studies in the United...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01477","BK1161","BK1574","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658198045","title":"Ascletis Pharma - U.S. FDA Clears Ind Applications for Asc36 and Asc36_35Fdc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658198045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658198045?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:50","pubTimestamp":1786359050,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470MZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658801059","title":"Ascletis Says FDA Clears INDs for Obesity Candidates Asc36, Asc36_35fdc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658801059","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658801059?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:50","pubTimestamp":1786359049,"startTime":"0","endTime":"0","summary":"Ascletis says FDA clears INDs for obesity candidates ASC36, ASC36_35FDCAscletis received US FDA IND clearance to start two Phase 1 obesity studies of ASC36 and monthly fixed-dose combo ASC36_35FDC.Tri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL55q8X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181390081","title":"Hong Kong Market Movers: Innovative Drug Stocks Rally as Earnings Season Approaches, Medical Conferences Expected to Provide Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1181390081","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181390081?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:36","pubTimestamp":1786073814,"startTime":"0","endTime":"0","summary":"Innovative drug stocks are broadly trending higher, with ZAI LAB (09688) surging 14.32% to HK$16.61, WUXI XDC (02268) climbing 9.48% to HK$60.65, and WUXI BIO (02269) advancing 6.19% to HK$43.94....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","LU0359201612.USD","KCAI","LU0456827905.SGD","LU0348825331.USD","IBBQ","LU0572944931.SGD","LU0052750758.USD","LU0456846285.SGD","BK1574","09688","LU0856984785.SGD","LU2488822045.USD","LU0516422366.SGD","SG9999014674.SGD","LU0359202008.SGD","LU1242518857.USD","LU1794554557.SGD","SG9999002463.SGD","LU0823426308.USD","LU0708995583.HKD","07666","BK1161","LU1880383366.USD","LU0326950275.SGD","LU0039217434.USD","LU0823426480.USD","01672","LU0043850808.USD","BK1610","LU3063872942.SGD","LU1688375341.USD","LU0327786744.USD","02269","LU0417516902.SGD","LU0516423091.SGD","BK1515","LU1242518931.SGD","LU1720050803.USD","BK1589","LU0516423174.USD","LNGR","BK1141","LU0979878070.USD","LU0516422952.EUR","MEDX","LU0051755006.USD","LU0140636845.USD","LU0348735423.USD","159992","06978","LU0181495838.USD","LU0307460666.USD","LU0516422440.USD","LU0588546209.SGD","SG9999002562.SGD","KURE","BK1576","BK1588","BK4588","BK4585","IE00B0JY6N72.USD","LU0320764599.SGD","LU0417516738.SGD","LU2039709279.SGD","02268","BK1521","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115862302","title":"Ascletis Pharma Shares Surge 5% on Global Phase 3 Trial Launch for GLP-1 Oral Drug ASC30","url":"https://stock-news.laohu8.com/highlight/detail?id=1115862302","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115862302?lang=en_us&edition=fundamental","pubTime":"2026-08-04 11:00","pubTimestamp":1785812435,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) shares rose more than 5% in early trading, recently gaining 4.89% to HK$9.44, with a turnover of approximately HK$20.63 million. On August 3, the company announced that its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","BK4144","GLP","BK4590","JDOC","BK1574","01672","01477","BK1191","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656487302","title":"Is Ascletis’ Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2656487302","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656487302?lang=en_us&edition=fundamental","pubTime":"2026-08-04 01:14","pubTimestamp":1785777280,"startTime":"0","endTime":"0","summary":"Ascletis Pharma recently reported that its next-generation triple peptide agonist ASC37 achieved greater weight loss than tirzepatide in diet‑induced obese mice, and outlined plans to file investigational new drug applications for both once‑monthly subcutaneous and oral formulations in the third quarter of 2026.\nThe company also highlighted that ASC37 and its dual agonist ASC35 qualify as biologics, potentially benefiting from longer U.S. exclusivity and reduced exposure to government price...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-biologic-obesity-pipeline-altering-the-investmen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-biologic-obesity-pipeline-altering-the-investmen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1515","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656868373","title":"Ascletis Announces Initiation of Global Phase Iii for Oral Small Molecule Glp-1, Asc30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule Glp-1/Gip/Amylin Fixed-Dose Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2656868373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656868373?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:55","pubTimestamp":1785754500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA3RZX2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656864373","title":"Ascletis Pharma - Has Sufficient Cash to Support Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2656864373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656864373?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:55","pubTimestamp":1785754500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA3RZX2G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373860","title":"Ascletis Pharma - Expects Asc30 Phase Iii Topline Data Q3 2028; Nda End 2028; Maa Early 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373860?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:55","pubTimestamp":1785754500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA3RZX2G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656780653","title":"Ascletis Pharma - Initiates Global Phase Iii for Asc30 in Obesity with 4,600 Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2656780653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656780653?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:51","pubTimestamp":1785754268,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44018I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656780923","title":"Ascletis Says FDA Clears Phase III Trials for Oral GLP-1 Obesity Drug ASC30","url":"https://stock-news.laohu8.com/highlight/detail?id=2656780923","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656780923?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:51","pubTimestamp":1785754267,"startTime":"0","endTime":"0","summary":"Ascletis says FDA clears Phase III trials for oral GLP-1 obesity drug ASC30Ascletis won FDA clearance to start global Phase III trials of oral GLP-1 candidate ASC30 for long-term weight management.Pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL38NMLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656537324","title":"Ascletis Pharma Schedules Board Meeting to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2656537324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656537324?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:41","pubTimestamp":1785746514,"startTime":"0","endTime":"0","summary":"Ascletis Pharma schedules board meeting to review interim results, consider dividendAscletis Pharma will hold a board meeting on Aug. 31, 2026 to review interim results for the six months ended June 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLbFZ9fH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878024","title":"Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878024","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878024?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:24","pubTimestamp":1785407053,"startTime":"0","endTime":"0","summary":"Ascletis Pharma files HKEX next-day disclosure return on share repurchase for cancellationAscletis filed a next-day disclosure return showing a 100,000-share buyback for cancellation on July 30.Repurc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL4hMHPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112778047","title":"ASCLETIS-B (01672) Spends HK$1.76 Million to Buy Back 200,000 Shares on July 29","url":"https://stock-news.laohu8.com/highlight/detail?id=1112778047","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112778047?lang=en_us&edition=fundamental","pubTime":"2026-07-29 17:48","pubTimestamp":1785318505,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced a share buyback transaction conducted on July 29, 2026.The company repurchased a total of 200,000 shares, spending approximately HK$1.7643 million in the process.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574","BK1161","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654019679","title":"Ascletis Pharma - Ind Applications for Asc37 Sq and Oral Formulations to be Submitted in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654019679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654019679?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:10","pubTimestamp":1785147033,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA7ZKFLL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654019628","title":"Ascletis Announces Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2654019628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654019628?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:10","pubTimestamp":1785147033,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA7ZKFLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":0.2485},{"period":"3month","weight":-0.3254},{"period":"6month","weight":-0.3705},{"period":"1year","weight":-0.4109},{"period":"ytd","weight":-0.0825}],"compareEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":0.0363},{"period":"3month","weight":-0.0134},{"period":"6month","weight":-0.0469},{"period":"1year","weight":0.0072},{"period":"ytd","weight":-0.0069}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.5,"avgChangeRate":0.001982},{"month":8,"riseRate":0.375,"avgChangeRate":-0.001772},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"ASCLETIS-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCLETIS-B,01672,ASCLETIS-B股票,ASCLETIS-B股票老虎,ASCLETIS-B股票老虎国际,ASCLETIS-B行情,ASCLETIS-B股票行情,ASCLETIS-B股价,ASCLETIS-B股市,ASCLETIS-B股票价格,ASCLETIS-B股票交易,ASCLETIS-B股票购买,ASCLETIS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}